−0.2063SEK
−79.79 MSEK
8.27 MSEK
1.44 B
About CLINICAL LASERTHERMIA SYSTEMS AB SER. B
Sector
Industry
CEO
Dan J. Mogren
Website
Headquarters
Lund
Founded
2006
ISIN
SE0002756130
FIGI
BBG001Y25W63
Clinical Laserthermia Systems AB engages in the development and manufacture of pharmaceutical products. It offers TRANBERG, a Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors that is marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy. The company was founded by Karl-Göran Tranberg, Lars-Erik Thomas Eriksson, and Per-Hakan Henriksson on March 9, 2006 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CLS_B is 0.0938 SEK — it has increased by 1.30% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange CLINICAL LASERTHERMIA SYSTEMS AB SER. B stocks are traded under the ticker CLS_B.
CLS_B stock is 17.16% volatile and has beta coefficient of 2.48. Check out the list of the most volatile stocks — is CLINICAL LASERTHERMIA SYSTEMS AB SER. B there?
CLINICAL LASERTHERMIA SYSTEMS AB SER. B revenue for the last quarter amounts to 2.00 M SEK despite the estimated figure of 3.50 M SEK. In the next quarter revenue is expected to reach 3.40 M SEK.
Yes, you can track CLINICAL LASERTHERMIA SYSTEMS AB SER. B financials in yearly and quarterly reports right on TradingView.
CLS_B stock has fallen by 6.94% compared to the previous week, the month change is a 15.52% rise, over the last year CLINICAL LASERTHERMIA SYSTEMS AB SER. B has showed a 93.75% decrease.
CLS_B net income for the last quarter is −25.25 M SEK, while the quarter before that showed −16.80 M SEK of net income which accounts for −50.28% change. Track more CLINICAL LASERTHERMIA SYSTEMS AB SER. B financial stats to get the full picture.
Today CLINICAL LASERTHERMIA SYSTEMS AB SER. B has the market capitalization of 145.41 M, it has decreased by 4.17% over the last week.
No, CLS_B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CLS_B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLINICAL LASERTHERMIA SYSTEMS AB SER. B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLINICAL LASERTHERMIA SYSTEMS AB SER. B technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLINICAL LASERTHERMIA SYSTEMS AB SER. B stock shows the sell signal. See more of CLINICAL LASERTHERMIA SYSTEMS AB SER. B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CLINICAL LASERTHERMIA SYSTEMS AB SER. B future price: according to them, CLS_B price has a max estimate of 0.30 SEK and a min estimate of 0.30 SEK. Read a more detailed CLINICAL LASERTHERMIA SYSTEMS AB SER. B forecast: see what analysts think of CLINICAL LASERTHERMIA SYSTEMS AB SER. B and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLINICAL LASERTHERMIA SYSTEMS AB SER. B EBITDA is −65.37 M SEK, and current EBITDA margin is −763.06%. See more stats in CLINICAL LASERTHERMIA SYSTEMS AB SER. B financial statements.